CD8A and neoplasm: When tumor sizes reached 100 mm3, E.G7 tumor-bearing mice were randomly divided into five groups: sorafenib alone (sora), 2×106 CD8+ T cells (2T), 5×106 CD8+ T cells (5T), 2×106 CD8+ T cells plus sorafenib (2T+sora), and vehicle control, to determine whether serial low doses of sorafenib could increase the accumulation and activation of transferred CD8+ T cells in target tumors in vivo.